ENPP2 and idiopathic pulmonary fibrosis: Ziritaxet, a new Autotaxin inhibitor, demonstrated encouraging results by reducing plasma lysophosphatidic acid concentrations in a Phase IIa study involving 23 patients with IPF (39).